Bio Path Holdings

Bio Path Holdings Current Ratio

Delisted·Sep 10, 2026

Current Ratio of Bio Path Holdings (BPTH) as of Oct 17, 2026.

Current Ratio

0.00

Last updated:

Current Ratio of Bio Path Holdings is 2024 0.00 . Current Ratio of Bio Path Holdings was 2023 0.91 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Path Holdings Stock analysis

What does Bio Path Holdings do? Bio Path Holdings Inc, listed under ticker BPTH, is a biotechnology company headquartered in Bellaire, Texas. It focuses on developing therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company has 10 employees and went public on January 11, 2006. Its technology, DNAbilize, delivers antisense drugs via a DNA backbone modification to protect against enzymatic destruction, enabling systemic distribution to target proteins in blood diseases and solid organs. The company has three antisense drug candidates in development for over five cancer disease indications. Bio Path Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Path Holdings stock

On Eulerpool you can find the complete historical development of Current Ratio Bio Path Holdings since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Bio Path Holdings with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio Path Holdings

All Key Metrics — Bio Path Holdings